CA 125 measurement in the follow-up of breast cancer patients

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 3099-3100

  Bohmer Ch ^a   Jager W ^a   Lang, N ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Breast cancer; CA 125; Follow up; Metastases; Screening; Second neoplasm

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ADULT; AGED; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; CA-125 ANTIGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 1842373265     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (9)

1. Alberico S, Facca MC, Millo R, Radillo L, Mandruzzato GP: Tumoral markers (CA 125 - CEA) in the screening of ovarian cancer. Eur J Gynaec Onco 9(6): 485-489, 1988.
2. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff J, Lazarus H, Berkowitz RS, Leavitt T, Griffiths T, Parker L, Zurawski VR Jr, Knapp RC: A radioimmunoassay using a monoclinoal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 883-887, 1983.
3. Bonadonna G, Valagussa P, Molitemi A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide,methotrexate and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332: 901-906, 1995.
4. Einhorn N, Sjovall K, Knapp RC, Hall P, Seully RE, Bast Jr RC, Zurawski Jr VR: Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80: 14-18, 1992.
5. Jacobs IJ et al: 3rd Int. Forum on ovarian cancer, Charleston, U.S.A. 1991, Yedema C et al: Update on the serum tumof marker CA 125. Sonderdruck des Free University Hospital Amsterdam 1993. Jager W. Kissing A, Cilaci S, Melsheimer R, Lang N: Is an increase in CA 125 in breast cancer patients an indicator for pleural metastases? Br.J.Cancer 70: 493-495, 1994.
6. Jacobs IJ et al: 3rd Int. Forum on ovarian cancer, Charleston, U.S.A. 1991, Yedema C et al: Update on the serum tumof marker CA 125. Sonderdruck des Free University Hospital Amsterdam 1993. Jager W. Kissing A, Cilaci S, Melsheimer R, Lang N: Is an increase in CA 125 in breast cancer patients an indicator for pleural metastases? Br.J.Cancer 70: 493-495, 1994.
7. Jacobs IJ et al: 3rd Int. Forum on ovarian cancer, Charleston, U.S.A. 1991, Yedema C et al: Update on the serum tumof marker CA 125. Sonderdruck des Free University Hospital Amsterdam 1993. Jager W. Kissing A, Cilaci S, Melsheimer R, Lang N: Is an increase in CA 125 in breast cancer patients an indicator for pleural metastases? Br.J.Cancer 70: 493-495, 1994.
8. Shapira MM, Matchar DB, Young MY: The effectiveness of ovarian cancer screening. A decision analysis model. Ann Intern Med 118: 939-843, 1993.
9. Zurawski VR, Knapp RC, Einhom N, Kenemans P, Mortel R, Ohmi K, Bast Jr RC, Ritts RE, Malkasian G: An initial analysis of preoperative serum ca 125 levels in patients with eariy stage ovarian carcinoma. Gynecologic oncology 30: 7-14, 1988.